ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Shareholder Director NominationsItem 5.08
On June12, 2018, the Board of Directors, or the Board, of Ziopharm Oncology, Inc., or the Company, approved September19, 2018 as the date of the Company’s 2018 Annual Meeting of Stockholders, or the Annual Meeting. Additionally, the Board approved July23, 2018 as the record date for the Annual Meeting.
Qualified stockholder proposals (including proposals made to Rule 14a-18 under the Securities Exchange Act of 1934, as amended) to be presented at the Annual Meeting and included in the Company’s proxy statement and form of proxy must be received at the Company’s principal executive offices located at One First Avenue, Parris Building 34, Navy Yard Plaza, Boston, MA 02129, addressed to the Company’s Secretary, not later than July20, 2018, which the Company has determined is a reasonable time before the Company begins to distribute the proxy materials for the Annual Meeting. Any such proposals must comply with applicable Delaware law, the rules and regulations promulgated by the Securities and Exchange Commission, and the procedures set forth in the Company’s By-laws.
On June18, 2018, the Company issued a press release announcing that the U.S. Food and Drug Administration placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and reported on the status of the Investigational New Drug application for such trial. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference
| Item 5.08 | Financial Statements and Exhibits |
|
Exhibit No. |
Description |
| 99.1 | Press Release dated June18, 2018. |
ZIOPHARM ONCOLOGY INC ExhibitEX-99.1 2 d206889dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy BOSTON,…To view the full exhibit click here
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
